Cell Therapy Platforms

Cell
Therapy
Platforms

Inceptor Bio is building a diversified cell therapy portfolio with differentiation that matters across multiple cell types including T cells, Macrophages, and Natural Killers.

A Differentiated Approach to CAR-T

Inceptor Bio’s CAR-T platform is based on a novel co-stimulatory domain platform, M-STIM, that generates expansion kinetics that are differentiated from the CAR-T therapies currently on the market.

An Innovative Approach to CAR-M

Inceptor Bio’s CAR-M platform enhances the unique capabilities of macrophages to target and engulf cancer cells.

Technology Platforms

Inceptor Bio has platforms in the below effector cells:

CAR-T

CAR-T

CAR-T cells are engineered to identify and kill cancer cells. There are multiple CAR-T therapies that have earned FDA approval.

CAR-M

CAR-M

CAR-Macrophages have the ability to access solid tumors, survive in their hostile environment, selectively destroy cancer cells, and activate an adaptive immune response by presenting engulfed tumor material.

CAR-NK

CAR-MK

CAR-Natural Killer cells are engineered to identify and attack cancer. Safety (avoiding GvHd) and accessibility (allogeneic) are two strong advantages.

Let’s

cure

cancer

together

Arrow

CONTACT US